Evidence map›Paper›PMID 21695781›Full record

ReviewSmall (Weinheim an der Bergstrasse, Germany)2011

More effective nanomedicines through particle design.

Jin Wang, James D Byrne, Mary E Napier, Joseph M DeSimone

Abstract readReview
In one paragraph

Review in Small (Weinheim an der Bergstrasse, Germany), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 133 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
133citing papers in PubMed, 1 pooled it
20.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

133 citing papers in PubMed, 1 synthesis or guideline pooled it, 478 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Characterizing the Impact of the Cell Cycle on mRNA Lipid Nanoparticles.Journal of the American Chemical Society · 2026
    Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Effect of spParticle and fibre toxicology · 2023
    Article
  19. Article
  20. Review

73 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Jin WangDepartment of Chemistry, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA.
James D Byrne
Mary E Napier
Joseph M DeSimone
University of North Carolina at Chapel Hill · USUNC Lineberger Comprehensive Cancer Center

Funding

"Smart" Nanoparticles for Cancer Therapy and ImagingU54CA119343 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LIU, RIHE · 2005 to 2009
$18.3M
Translational Nanosystems for Improved Lung Cancer Treatment with Small MoleculesU54CA151652 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DESIMONE, JOSEPH M. · 2010 to 2014
$12.1M
TRANSPORT AND DELIVERY OF ANTISNESE OLIGONUCLEOTIDESP01GM059299 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JULIANO, RUDOLPH · 2000 to 2010
$11.7M
Delivery of Biological Therapeutics: Using Engineered Particles and Novel DeliverDP1OD006432 · OD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DESIMONE, JOSEPH M. · 2009 to 2011
$2.2M
Delivery of Biological Therapeutics: Using Engineered Particles and Novel DeliverDP1CA174425 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DESIMONE, JOSEPH M. · 2012 to 2013
$1.4M
Engineered Organic Particles of Controlled Size, Shape and Surface Chemistry for R01EB009565 · NIBIB · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DESIMONE, JOSEPH M. · 2009 to 2012
$1.3M
Biomimetic Approach to the Fabrication of Red Blood Cell MimicsR21HL092814 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DESIMONE, JOSEPH M. · 2009 to 2010
$724k
Red Blood Cell MimicsR21HL096011 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DESIMONE, JOSEPH M. · 2010 to 2011
$382k
NCI NIH HHS DP1 CA174425NCI NIH HHS U54 CA119343NCI NIH HHS U54-CA119343NCI NIH HHS U54 CA151652NHLBI NIH HHS R21 HL092814NHLBI NIH HHS R21 HL096011NIBIB NIH HHS R01 EB009565NIBIB NIH HHS R01-EB009565NIGMS NIH HHS P01 GM059299NIGMS NIH HHS P01-GM059299NIH HHS DP1 OD006432
6 · The paper itself

Abstract

Nanomedicine is an emerging field that applies concepts in nanotechnology to develop novel diagnostics and therapies. Physical and chemical properties of particles, including size, shape, modulus, surface charge and surface chemistry, play an important role in determining particle-cell interactions, cellular trafficking mechanisms, biodistribution, and pharmacokinetics. This discussion focuses on both nanoparticles and microparticles since microparticles can also provide many insights for the development of drug carriers and possess advantages over nanoparticles in certain applications. This review covers recent major advancement in the nanomedicine field and also highlights studies using the PRINT technology.

Indexed as

CellsDrug DesignEndocytosisNanomedicineNanoparticlesTissue Distribution

Identifiers

PMID21695781
PMCPMC3136586
OpenAlexW2165031969

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.